The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

U.S. Market Expected to Grow from USD 0.81 Billion to USD 3.31 Billion by 2035; Europe Market Forecast to Reach USD 2.18 Billion as Advanced Therapy Research Expands.Austin, United States, June 09, ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

The cell and gene therapy CDMO market is experiencing significant growth, driven by the increasing number of cell and gene therapy candidates advancing through clinical development and ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a ...

CDMO ProBio, the biologics subsidiary of GenScript, opened a new plasmid DNA and viral vector production manufacturing facility in Hopewell, New Jersey. (ProBio) CDMO ProBio, the biologics subsidiary ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...